 |
 |
 |
|
CellerateRx™ Activated CollagenNon-prescription wound care
The ACTIVATED COLLAGEN in CellerateRx™ Powder and Gel is changing collagen’s role in the art of advanced woundcare.
CellerateRX’s patented collagen fragments (CRXα), are a fraction of the size of the native collagen molecules and particles found in other products, delivering the benefits of collagen to the body immediately.
Benefits:
- CRXa ™ activates the collagen which brings benefits immediately to the wound bed. Native intact collagen requires time for the body to break it down, delaying the body’s ability to use it in the healing process.
- CRXα helps jump start collagen’s role in wound bed processes and enables CellerateRx™ products to exceed the expectations of both clinicians and patients through all phases of wound healing.
·
Unprecedented performance:
- CRXα provides collagen’s benefits immediately to the wound bed
- The size and form of CRXα helps jump start collagen’s role in wound bed processes
Unprecedented range of use:
- Frontline therapy, from first dressing to closure
- Compatible with known single-objective therapies, including: silvers, debriders, grafts and skin substitutes
Unprecedented cost savings:
- Fewer required dressing changes translates to lower staffing and materials costs
- CRXα performs effectively with even the least costly secondary dressings such as gauze
For use in the management of chronic wounds and skin ulcers, including pressure ulcers (Stages I-IV), venous stasis ulcers, diabetic ulcers, ulcers resulting from arterial insufficiency, surgical wounds, traumatic wounds, first and second degree burns, and superficial wounds.
CellerateRx has been cleared by the Food and Drug Administration for Stage I-IV pressure ulcers.
For acute and chronic wounds which include, but not limited to:
Pressure Ulcers Stage 1 to Stage IV, Traumatic Wounds, Diabetic Ulcers,1st and 2d degree burns, Surgical wounds, Venous Stasis Ulcers, Ulcers due to arterial insufficiency, Superfical wounds.
Gel
- Donates moisture, forms occlusive barrier
- Maintains moist environment and promotes autolytic debridement
- 100% biodegradable and synthetic free. Does not require removal from wound site
- Effective in all wound phases/states: inflamation, proliferation, maturation / necrotic, infected, granulating, remodelling
Powder- Mixes with wound exudates, absorbing up to 30x its own weight. Forms occlusive barrier
- Mixes with exudates and promotes autolytic debridement
- 100% biodegradable and synthetic free. Does not require removal from wound site
- Effective in all wound phases / states: Inflamation, proliferation, proliferation, maturation / necrotic, infected, granulating, remodelling
| Description | Size (gm) | Form | Product Code | HCPC | | 1 gram Powder Bottle | 1 | Powder | 500 | A6010 | | 5 gram Powder Bottle | 5 | Powder | 501 | A6010 | | 20 gram Powder Bottle | 20 | Powder | 502 | A6010 | | 40 gram Powder Bottle | 40 | Powder | 503 | A6010 | | 28 gram Gel Tube | 28 | Gel | 401 | A6011 | | 6 gram Gel Tube | 6 | Gel | 400 | A6011 | | Packers: | | 1gm Powder Packer | 24 x 1 gram | Powder | 5005 | A6010 | | 5gm Powder Packer | 12 x 5 gram | Powder | 5012 | A6010 |
Application ProtocolInitial Application: Debride wound. Powder: Completely cover moist wound bed with CellerateRx ™ powder. Gel: apply generously to wound bed. Cover gel or powder with a non-stick type dressing appropriate for level of drainage. |
|
|
|
|
|
|
|
|
